El-Menyar Ayman, Khan Naushad A, Al Mahmeed Wael, Al Suwaidi Jassim, Al-Thani Hassan
Clinical Research, Vascular Surgery, Hamad Medical Corporation, Doha, Qatar; Clinical Medicine, Weill Cornell Medicine, Doha, Qatar.
Clinical Research, Vascular Surgery, Hamad Medical Corporation, Doha, Qatar.
JACC Asia. 2025 Jul;5(7):847-864. doi: 10.1016/j.jacasi.2025.04.012.
Dyslipidemia, a significant risk factor for cardiovascular diseases (CVDs), is prevalent in the Middle East (ME) countries. With a variable prevalence, elevated lipoprotein (a) [Lp(a)] is the most widespread monogenic dyslipidemic disorder. Genetic studies have established Lp(a) as a heritable and independent risk factor for CVD. This discovery has shifted the perception of Lp(a) and the LPA gene from mere biomarkers of atherosclerotic risk to a viable target for therapeutic intervention. Significant differences in serum Lp(a) levels have been observed across racial and ethnic groups, with few independent genetic variants affecting Lp(a) levels outside the LPA gene region. Data specific to the ME and Arab populations remains scarce. ME populations exhibit genetic diversity and higher consanguinity rates, which may uniquely influence Lp(a) distribution and associated variations. This review examines the genetic and observational factors that shape Lp(a) levels and their role in CVD risk, focusing on ME populations.
血脂异常是心血管疾病(CVD)的一个重要危险因素,在中东(ME)国家普遍存在。脂蛋白(a)[Lp(a)]升高是最常见的单基因血脂异常疾病,其患病率各不相同。基因研究已将Lp(a)确立为CVD的遗传和独立危险因素。这一发现已将对Lp(a)和LPA基因的认识从动脉粥样硬化风险的单纯生物标志物转变为治疗干预的可行靶点。不同种族和民族的血清Lp(a)水平存在显著差异,在LPA基因区域之外,几乎没有影响Lp(a)水平的独立基因变异。关于中东和阿拉伯人群的具体数据仍然很少。中东人群表现出遗传多样性和较高的近亲结婚率,这可能会独特地影响Lp(a)的分布及相关变异。本综述探讨了影响Lp(a)水平的遗传和观察因素及其在CVD风险中的作用,重点关注中东人群。
Int Urol Nephrol. 2025-3-24
Cochrane Database Syst Rev. 2024-3-27
Cochrane Database Syst Rev. 2022-2-24
Eur J Prev Cardiol. 2025-7-14
Curr Cardiovasc Risk Rep. 2025-12
JACC Asia. 2024-9-10
Int J Vasc Med. 2024-10-12
Curr Heart Fail Rep. 2024-12
J Lipid Atheroscler. 2024-9
Lancet. 2024-9-28